A recent study compared the risk of having a second cancer after treatment using either intensity-modulated radiotherapy, 3-dimensional conformal radiotherapy, or proton beam radiotherapy.
What Are Circulating Tumor Cells?
Circulating tumor cells (CTCs) are cancer cells that detach from a primary cancer tumor and enter a person’s bloodstream. Their goal is to move to another part of the body to form new metastases. These new metastatic lesions are more aggressive than the primary tumor and account for most of the cancer-related deaths.
FDA Approves A New Lung Cancer Drug - Vizimpro
The FDA Approves A New Lung Cancer Drug -Vizimpro
Pazopanib Shows Promise in von Hippel-Lindau Disease - A Rare Cancer Syndrome
How to Recognize and Cope with Cancer Distress
A typical reaction that we have to cancer is to become distressed. When feeling high levels or constant distress, you often feel as though you can’t handle the problems that you are facing. Stress is manifested in many different ways; mentally, physically, socially, or spiritually—or in any combination of these ways.
Medicare Home Healthcare Benefits
Terminal Cancer: Putting Numbers to The Emotional Toll of A Caregiver
Appendix Cancer Gene Mutations Might Guide Treatment
PARP Inhibitors Might Treat Two Rare Cancers
The European Union & Gadolinium In MRIs
The NHS in Scotland Has Turned Down Two Rare Cancer Drugs
Afatinib Approval Expanded for Rare Lung Cancer Subset
Immunotherapy Highly Effective In The Treatment Of A Rare Melanoma Skin Cancer
Molecular Analysis Offers Treatment Hints for Rare Nasal Cavity Cancer
Even One Alcoholic Drink Raises Your Cancer Risk
The American Society of Clinical Oncology (ACSO), warns that people drinking alcoholic drinks face a significantly increased risk of developing cancer(s).
FOUNDATION ONE CDx – A NEW BROAD BRUSH GENETIC TEST TO HELP MAKE BETTER TREATMENT DECISIONS
Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.
Animal Models Show That Cancer Itself Can Impact Memory – It's Not Just Chemo Brain!
Shingrix – A new and Better Shingles Vaccine
We Demand That Our Doctors SEE US
An article in Healio (10/23) reported the results of a study of 120 cancer patients “nearly three-quarters of patients with advanced cancer preferred doctors who communicated with them face-to-face while holding a notepad rather than repeatedly using a computer.”
Hello, why the surprise here?
In a presentation scheduled to be delivered at the Palliative and Supportive Care in Oncology Symposium, Andrew S. Epstein, MD, ASCO expert and medical oncologist at Memorial Sloan Kettering Cancer Center, said of the research implications, “In an age of ubiquitous technology, this study is an important reminder of the need to address the potential for technology to interfere with the patient-clinician interface, which is a critical component of the relationship between these two parties.”
Look, we already know this fact. The real question for us isn’t the research finding, but what we need to do if we find that our doctor doesn’t speak with us but instead engages with the computer screen.
Usually, physicians engage with the computer during our meetings with them so that their notes are up to date without needing to take a few seconds afterward and update their notes. Doctors who engage in this practice are being selfish.
Forget our personal preferences that we want to feel that our doctors engage with us; there is good evidence that a doctor can gain as much valuable clinical information about us by carefully observing us as well as listening to what we say to them.
The standard of care should dictate that our clinical caregivers engage us, not their computer.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer
a rare cancer.
